NEW YORK – Revvity said Thursday that it will provide DNA sequencing services to help identify rare genetic conditions in newborns for Genomics England's Generation Study.

纽约——Revvity周四表示，将为Genomics England的Generation Study提供DNA测序服务，以帮助识别新生儿的罕见遗传疾病。

The study involves the screening of up to 100,000 newborns for more than 200 rare genetic disorders, and the findings will be used to inform decisions on the use of whole-genome sequencing in newborn screening.

该研究涉及对多达10万名新生儿进行200多种罕见遗传疾病的筛查，研究结果将用于指导在新生儿筛查中使用全基因组测序的决策。

The new agreement expands on a previous partnership

新协议扩大了之前的合作伙伴关系

announced in November

十一月宣布

under which Revvity's Omics laboratory in Manchester, UK, would extract DNA from cord blood from samples collected from newborns for the study.

根据该协议，Revvity位于英国曼彻斯特的Omics实验室将从为研究收集的新生儿脐带血样本中提取DNA。

Revvity said it will now be able to provide an end-to-end sample prep and sequencing solution with a localized lab facility. According to its website, Revvity's newborn sequencing research workflow comprises sample collection and extraction, laboratory LIMS, sample quality control and quantification, automated library preparation and QC, sequencing using Element Biosciences and Illumina platforms, and bioinformatics analyses..

Revvity表示，现在将能够通过本地化的实验室设施提供端到端的样本制备和测序解决方案。根据其官网介绍，Revvity的新生儿测序研究工作流程包括样本采集与提取、实验室LIMS系统、样本质量控制与定量、自动化文库制备与质控、使用Element Biosciences和Illumina平台进行测序，以及生物信息学分析。

'Our complete solution and localized lab facility help us deliver timely and reliable sequencing data in support of this critical program that strengthens newborn health,' Madhuri Hegde, Revvity's senior VP and CSO, said in a statement. 'Revvity's expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programs.'.

“我们全面的解决方案和本地化的实验室设施帮助我们及时提供可靠的支持这一关键项目加强新生儿健康的测序数据，”Revvity公司的高级副总裁兼首席战略官Madhuri Hegde在一份声明中说道，“Revvity广泛的全球实验室网络结合我们用于新生儿筛查的下一代测序解决方案和工作流程，使我们能够引领这一及类似举措，为未来的项目设定标准。”

Financial terms of the agreement were not disclosed.

协议的财务条款未披露。